thumbnail image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
    • LungCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
      • LungCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
    • LungCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
      • LungCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
  • LungCanSeekTM

    Blood-based lung cancer early detection service

    Lung cancer is the leading cause of cancer mortality worldwide. The 5-year survival rate for advanced lung cancer is less than 20%, while the survival rate for early-stage lung cancer is over 60%. Early screening for lung cancer is key to extending patient survival and lowering mortality rates.

    LungCanSeekTM is an artificial intelligence (AI)-driven early lung cancer screening service designed to identify cancer at its curable stage, enabling timely intervention to improve clinical outcomes.

    Al-powered

    Non-invasive

    Early detection

    Cost-effective

  • Highlights

    • LungCanSeekTM calculates a probability of lung cancer (POLC) index by precisely analyzing the levels of four lung cancer related protein tumor markers (PTMs).
    • When cancer signal is detected, LungCanSeekTM can predict main lung cancer subtypes: lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and small cell lung cancer (SCLC).

    LungCanSeekTM offering 83.5% sensitivity, 90.3% specificity, and 77.4% subtype classification accuracy. Its can be utilized for the initial screening, followed by low-dose computed tomography (LDCT) for the individuals who tested positive in the initial screening. This two-step approach capitalizes on LungCanSeekTM's ease to perform, low cost, and high specificity to mitigate LDCT's false positive issue.

  • Indicated subjects

    Smoked at least a pack a day for 20 years

    Significant secondhand smoke exposure

    High exposure

    to indoor pollutants

    (e.g., cooking

    oil fumes)

    Exposure to environmental carcinogens

    (e.g., radon, asbestos)

    History of chronic obstructive pulmonary disease (COPD) or pulmonary fibrosis

    Family history of lung cancer

  • Specifications

    ◉ Sample requirement: 4ml peripheral blood

    ◉ Result readout: probability of lung cancer (POLC)

    ◉ Turnaround time (TAT): 5 working days

  •  

    How it works

    Section image

    Customer order

    Customers can place orders through SeekIn official website or local agents

    Section image

    Blood-draw

    4ml venous peripheral blood collected in cell-free DNA BCT and can be stably stored at room temperature for 7 days

    Section image

    Testing

    Detection by Roche cobas e411 instrument

    Section image

    Reporting

    The test results will be ready in about 5 workdays after your blood draw arrived at central lab

  • Please review the instructions to gain a better understanding of LungCanSeekTM and assess whether it meets your needs.

    Download the Instructions

Navigation

Technology   

SeekInCare

SeeInCure

SeekInClarity

OncoSeek

Research

Contact Us

10320 Camino Santa Fe, Suite G

San Diego, CA 92121

United States

info@seekincancer.com

© 2024 SeekIn Inc.

All Rights Reserved.

Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More